Workspaces
Log in Sign up

FDA Compounding Committee Overrides Staff Objections to Recommend Six Peptides for Bulk Compounding

Updated

Sources

FDA Compounding Committee Overrides Staff Objections to Recommend Six Peptides for Bulk Compounding

In a significant policy and regulatory shift, the FDA's Pharmacy Compounding Advisory Committee (PCAC) concluded a high-stakes two-day meeting on July 23–24, 2026, by voting to recommend adding six of seven unapproved peptides under review to the Section 503A Bulk Drug Substances List. This list outlines bulk substances that licensed compounding pharmacies can legally use to formulate custom medications.

The committee’s decisions represent an unprecedented override of career FDA staff and scientists, who had formally recommended against including any of the seven peptides, citing severe gaps in human clinical safety data1, potential immunogenicity risks, and concerns regarding oncogenic promotion.

The six peptides recommended for inclusion, along with their narrow voting margins, are:

  1. BPC-157 (synthetic peptide derived from human gastric juice, proposed for ulcerative colitis and tissue repair): Recommended 8–6, with 1 abstention.
  2. TB-500 (synthetic fragment of the tissue-repair protein thymosin beta-4, proposed for wound healing): Recommended 8–6, with 1 abstention.
  3. KPV (tripeptide fragment of alpha-MSH, proposed for wound healing and inflammatory conditions): Recommended 8–6, with 1 abstention.
  4. MOTS-c (mitochondrial-derived peptide, proposed for obesity and osteoporosis): Recommended 7–5, with 2 abstentions.
  5. Semax (synthetic ACTH-derived peptide, proposed for cerebral ischemia, migraine, and facial pain): Recommended 8–5.
  6. Epitalon (synthetic tetrapeptide, proposed for insomnia and anti-aging): Recommended 7–4.

The only peptide rejected by the panel was emideltide (delta sleep-inducing peptide / DSIP), which was voted down 7–6 with 1 abstention.

Observers in the room noted that a PCAC panel has rarely, if ever, voted so consistently against FDA staff's written recommendations. The decision reflects a broader regulatory shift, potentially aligned with the administrative priorities of HHS Secretary Robert F. Kennedy, Jr., who has expressed a desire to broaden access to alternative wellness therapies.2

However, the PCAC recommendations are non-binding and do not make the peptides immediately legal or approved. Compounding pharmacies must wait for the FDA to finalize the recommendations through formal administrative rulemaking before they can legally compound these substances.

Key Quotes

"The FDA's Pharmacy Compounding Advisory Committee (PCAC) closed its July 23-24 meeting with a string of narrow votes recommending 6 of the 7 peptides under review—BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon—for the agency's 503A Bulks List, overriding career scientists who had recommended against including any of the 7." — AJMC Report

"PCAC passage for BPC-157, KPV, TB-500, MOTS-c, epitalon, and semax does not alter current legality; 503A Bulks List updates require formal FDA rulemaking before compounding is permitted." — Pharmacy Times Analysis

  1. An instance of Rigid regulatory objections collapse when independent advisory panels prioritize high unmet clinical need. — An independent compounding advisory panel chose to ignore warnings from FDA staff in order to recommend six alternative peptides for compounding. ↩︎

  2. An instance of Leadership churn at regulatory agencies triggers a systemic softening of clinical standards. — An advisory committee voted against career FDA scientists to recommend compounding peptides, indicating a policy shift driven by new administrative priorities. ↩︎

Part of

This finding is an example of a pattern recurring across your work:

Revision history

  • Update the peptide compounding advisory committee note to reflect the final votes, the specific peptides recommended vs. rejected, and the regulatory implications.
    · by the agent
  • Update the peptide compounding advisory committee note to reflect the final votes, the specific peptides recommended vs. rejected, and the regulatory implications.
    · by the agent
  • Update the peptide compounding advisory committee note to reflect the final votes, the specific peptides recommended vs. rejected, and the regulatory implications.
    · by the agent
  • Update the peptide compounding advisory committee note to reflect the final votes, the specific peptides recommended vs. rejected, and the regulatory implications.
    · by the agent
  • Update the peptide compounding advisory committee note to reflect the final votes, the specific peptides recommended vs. rejected, and the regulatory implications.
    · by the agent
  • Update the peptide compounding advisory committee note to reflect the final votes, the specific peptides recommended vs. rejected, and the regulatory implications.
    · by the agent
  • Update the peptide compounding advisory committee note to reflect the final votes, the specific peptides recommended vs. rejected, and the regulatory implications.
    · by the agent
  • Update the peptide compounding advisory committee note to reflect the final votes, the specific peptides recommended vs. rejected, and the regulatory implications.
    · by the agent
  • Update the peptide compounding advisory committee note to reflect the final votes, the specific peptides recommended vs. rejected, and the regulatory implications.
    · by the agent
  • Update the peptide compounding advisory committee note to reflect the final votes, the specific peptides recommended vs. rejected, and the regulatory implications.
    · by the agent
  • Update the peptide compounding advisory committee note to reflect the final votes, the specific peptides recommended vs. rejected, and the regulatory implications.
    · by the agent
  • Update the peptide compounding advisory committee note to reflect the final votes, the specific peptides recommended vs. rejected, and the regulatory implications.
    · by the agent
  • Create a new note detailing the FDA Pharmacy Compounding Advisory Committee's landmark recommendations to add six peptides to the 503A bulk compounding list, overriding FDA staff objections.
    · by the agent